Explore 3 Stock Ideas & Industry Insights Download Free Report

Cytek Biosciences Inc

Healthcare US CTKB

4.07USD
0.21(5.44%)

Last update at 2026-06-23T20:00:00Z

Day Range

3.884.12
LowHigh

52 Week Range

2.376.18
LowHigh

Fundamentals

  • Previous Close 3.86
  • Market Cap587.47M
  • Volume1453289
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-32.80500M
  • Revenue TTM201.49M
  • Revenue Per Share TTM1.58
  • Gross Profit TTM 104.46M
  • Diluted EPS TTM-0.52

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -29.84100M -5.70000M -15.70900M 1.26M 5.95M
Minority interest 0.00000M 0.00000M -0.18900M -0.09200M -0.02600M
Net income -66.53900M -6.02000M -12.14800M 2.58M 4.42M
Selling general administrative 58.94M 43.11M 43.97M 34.69M 20.82M
Selling and marketing expenses 49.44M 49.11M 49.15M 33.23M 24.71M
Gross profit 104.46M 111.11M 109.43M 100.97M 79.14M
Reconciled depreciation 11.97M 10.49M 8.67M 5.66M 1.24M
Ebit -29.36700M -20.52300M -13.63800M -1.82600M 6.45M
Ebitda -17.39200M -10.03300M -4.40800M 3.83M 7.69M
Depreciation and amortization 11.97M 10.49M 9.23M 5.66M 1.24M
Non operating income net other - - - 5.64M 0.05M
Operating income -40.38400M -20.52300M -27.84500M -1.82600M 6.45M
Other operating expenses 241.88M 220.98M 220.86M 165.84M 118.78M
Interest expense 0.47M 5.24M 2.07M 2.57M 1.74M
Tax provision 36.70M 0.32M -1.77300M -1.22400M 1.50M
Interest income 2.22M 10.36M 7.59M 4.62M 0.05M
Net interest income 1.74M 10.36M 5.23M 2.05M -1.69200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 36.70M 0.32M -3.56100M -1.22400M 1.50M
Total revenue 201.49M 200.45M 193.01M 164.04M 127.95M
Total operating expenses 144.84M 131.63M 137.27M 102.78M 69.98M
Cost of revenue 97.03M 89.35M 83.59M 63.06M 48.81M
Total other income expense net 10.54M 14.82M 12.14M 3.09M -0.49900M
Discontinued operations - - - - -
Net income from continuing ops -66.53900M -6.02000M -13.93300M 2.48M 4.44M
Net income applicable to common shares - - - 2.58M 0.05M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 461.54M 499.50M 497.67M 519.48M 463.70M
Intangible assets 16.82M 20.13M 23.08M 4.33M 4.74M
Earning assets - - - - -
Other current assets 9.91M 14.10M 12.32M 12.95M 5.50M
Total liab 119.80M 103.76M 104.61M 93.93M 56.90M
Total stockholder equity 341.74M 395.74M 393.06M 425.30M 406.46M
Deferred long term liab - - - 13.12M 9.79M
Other current liab 31.22M 33.08M 24.93M 27.74M 6.79M
Common stock 0.13M 0.13M 0.13M 0.14M 0.13M
Capital stock 0.13M 0.13M 0.13M 0.14M 0.13M
Retained earnings -101.73800M -35.19900M -29.17800M -17.03000M -18.19000M
Other liab - - - 30.31M 24.74M
Good will 16.70M 16.66M 16.18M 10.14M 10.14M
Other assets - - 0.00000M 21.82M 10.91M
Cash 90.85M 98.72M 167.63M 296.60M 364.62M
Cash and equivalents - - - - -
Total current liabilities 77.80M 67.66M 56.23M 49.04M 32.16M
Current deferred revenue 28.50M 25.49M 22.70M 12.99M 7.08M
Net debt -57.82900M -81.70000M -134.45600M -278.50700M -364.61800M
Short term debt 11.67M 8.41M 5.57M 3.51M 15.25M
Short long term debt 6.30M 4.66M 0.56M 0.58M -
Short long term debt total 33.02M 17.02M 33.17M 18.09M -
Other stockholder equity 441.11M 430.79M 423.39M -76.58900M -39.68000M
Property plant equipment - - - 13.68M 5.85M
Total current assets 392.00M 396.45M 392.06M 454.02M 432.05M
Long term investments - - - - -
Net tangible assets - - - 411.07M 391.57M
Short term investments 170.68M 179.15M 95.11M 44.55M -
Net receivables 72.13M 60.59M 56.12M 48.86M 29.76M
Long term debt 0.53M 1.05M 1.65M 2.27M -
Inventory 48.43M 43.89M 60.88M 48.15M 32.17M
Accounts payable 6.41M 5.53M 3.03M 4.80M 3.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.24M 0.02M -1.27500M -0.69700M 0.90M
Additional paid in capital - - - - -
Common stock total equity - - - 0.14M 0.13M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -17.03000M -19.60600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 6.70M 4.76M 1.78M 2.96M 1.67M
Deferred long term asset charges - - - - -
Non current assets total 69.55M 103.05M 105.61M 65.46M 31.65M
Capital lease obligations 16.92M 11.31M 11.92M 12.31M -
Long term debt total - - - 2.27M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 14.06M -82.97400M -174.02400M -1.58700M -20.99300M
Change to liabilities - - - 18.74M 20.73M
Total cashflows from investing activities 10.12M -82.97400M -93.89400M -55.90900M -20.99300M
Net borrowings 0.84M 3.62M -0.56500M 2.93M -2.77200M
Total cash from financing activities -13.43200M -15.82200M -41.81200M 5.51M 213.56M
Change to operating activities - - - -13.80400M 1.03M
Net income -66.53900M -6.02000M -12.14800M 2.48M 3.03M
Change in cash -7.89200M -68.88500M -131.87000M -65.11800M 198.50M
Begin period cash flow 98.75M 167.63M 299.50M 364.62M 166.12M
End period cash flow 90.85M 98.75M 167.63M 299.50M 364.62M
Total cash from operating activities -4.68600M 25.38M 5.28M -12.23100M 4.63M
Issuance of capital stock - - 0.00000M 0.00000M 215.69M
Depreciation 11.97M 10.49M 9.23M 5.66M 1.24M
Other cashflows from investing activities -0.10700M 0.08M -0.17900M -44.57400M -16.62900M
Dividends paid - - 1.47M - -
Change to inventory -5.24400M 14.76M 4.29M -17.65300M -7.06800M
Change to account receivables 0.37M -5.42800M -7.33200M -19.74400M -12.36700M
Sale purchase of stock -15.07400M -21.61100M -44.15100M 1.20M 216.33M
Other cashflows from financing activities -0.66900M 2.17M 2.90M 4.36M 0.64M
Change to netincome - - - 17.35M 7.07M
Capital expenditures 4.08M 3.52M 4.83M 9.87M 4.36M
Change receivables - - - -19.74400M -12.36700M
Cash flows other operating - - - -15.90400M -8.57800M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -62.62700M 197.20M
Change in working capital -4.79400M 7.71M -10.50900M -39.92800M -8.64600M
Stock based compensation 24.59M 26.85M 22.05M 16.59M 6.59M
Other non cash items -3.47000M -10.76600M -3.34000M 2.96M 1.97M
Free cash flow -8.77000M 21.85M 0.45M -22.09900M 0.27M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CTKB
Cytek Biosciences Inc
0.21 5.44% 4.07 - 370.37 2.92 1.72 1.74 222.69
ABT
Abbott Laboratories
2.70 3.07% 90.53 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation
5.31 1.74% 310.00 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC
1.36 1.72% 80.63 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp
1.27 2.86% 45.60 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

Profile

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Cytek Biosciences Inc

47215 Lakeview Blvd, Fremont, CA, United States, 94538-6407

Key Executives

Name Title Year Born
Dr. Wenbin Jiang Ph.D. Pres, CEO & Chairman 1964
Mr. Patrik Sebastian Jeanmonod Chief Financial Officer 1966
Dr. Ming Yan Ph.D. CTO & Director 1963
Dr. Allen B. Poirson Ph.D. Sr. VP of Bus. & Corp. Devel. 1960
Mr. Chris Williams Chief Operating Officer NA
Mr. Mark Edinger VP of Scientific Affairs NA
Mr. Paul D. Goodson Head of Investor Relations NA
Ms. Valerie T. Barnett J.D. Gen. Counsel & Corp. Sec. 1975
Ms. Connie Wedel Chief People Officer NA
Mr. Todd Garland Chief Commercial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions